Publications by authors named "S Di Tizio"
Background: We assessed the effectiveness, safety and patient-reported outcomes (PROs) of dimethyl fumarate (DMF) in real-world clinical practice in patients with multiple sclerosis (PwMS) from Argentina.
Methods: We conducted a multicenter ambispective cohort study in Argentina between September 2020 and March 2023. Changes in annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) score, magnetic resonance imaging (MRI), no evidence of disease activity (NEDA), PROs (depression, anxiety, fatigue, burden of treatment and quality of life), and safety data were collected at clinical visits performed every 6 months for at least 24 months.
Background: Knowledge of the safety and efficacy of disease-modifying therapies (DMTs) in older patients with Multiple Sclerosis (pwMS) is limited due to their exclusion from clinical trials. Our purpose is to evaluate the choice of DMTs in pwMS older than 50 years old in a real-world setting.
Methods: Cross-sectional study of pwMS from the Argentine MS and NMOSD Registry.
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease of the central nervous system characterized by severe attacks of optic neuritis, myelitis, and/or area postrema. Advances in understanding the pathophysiology of NMOSD have led to improved diagnostic and therapeutic approaches. There has been a notable increase in research efforts worldwide, including in Latin America (LATAM).
View Article and Find Full Text PDFArticle Synopsis
- Disease-modifying therapies (DMTs) for multiple sclerosis (MS) are classified by their effectiveness, with high-efficacy treatments (HETs) having limited data in Latin America, particularly Argentina.
- A study using the RelevarEM registry found that 19% of 2,450 patients with relapsing-remitting MS (RRMS) were on HETs, with many switching due to treatment failures, leading to a significant increase in HET usage from 11.65% to 29.55% over two time periods.
- The research highlighted rapid growth in HET adoption, with the most common treatments being alemtuzumab and cladribine, and emphasized understanding the demographics
Background: We aimed to determine the proportion of highly active multiple sclerosis patients under high-efficacy therapies (HETs) achieve no evidence of disease activity-3 (NEDA-3) at 1 and 2 years, and to identify factors associated with failing to meet no evidence of disease activity 3 at 2 years.
Methods: This retrospective cohort study based on Argentina Multiple Sclerosis patient registry (RelevarEM), includes highly active multiple sclerosis patients who received HETs.
Results: In total, 254 (78.